Qiagen (QGEN)
Market Price (7/7/2026): $39.145 | Market Cap: $8.1 BilSector: Health Care | Industry: Life Sciences Tools & Services
Qiagen (QGEN)
Market Price (7/7/2026): $39.145Market Cap: $8.1 BilSector: Health CareIndustry: Life Sciences Tools & Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.0%, FCF Yield is 5.0% Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 24% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19% Low stock price volatilityVol 12M is 32% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -43%, 3Y Excs Rtn is -82% | Key risksQGEN key risks include [1] navigating specific regulatory hurdles such as IVDR, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.0%, FCF Yield is 5.0% |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 24% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 29%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 19% |
| Low stock price volatilityVol 12M is 32% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Advanced Diagnostics, Personalized Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -43%, 3Y Excs Rtn is -82% |
| Key risksQGEN key risks include [1] navigating specific regulatory hurdles such as IVDR, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Qiagen (QGEN) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Mixed fiscal Q1 2026 Performance and Revised Full-Year Outlook.
Qiagen (QGEN) reported adjusted diluted EPS of $0.54 for fiscal Q1 2026 (ended March 31, 2026), which was in line with some analyst estimates but missed others by approximately 1.82% to 2.09%. While reported net sales increased 2% to $492 million, they declined 1% at constant exchange rates (CER) against an outlook for at least 1% CER growth, also falling short of consensus estimates. This mixed performance led the company to revise its full-year 2026 outlook, reducing expected net sales growth to about 1-2% CER (from at least 5% CER) and lowering adjusted diluted EPS expectations to at least $2.43 CER (from at least $2.50 CER). This downward adjustment in guidance likely tempered investor enthusiasm, contributing to the stock's stable trend rather than upward momentum.
2. Significant Decline in QuantiFERON Sales and U.S. Life Sciences Customer Caution.
A primary factor behind the revised outlook was a notable 5% CER decline in QuantiFERON sales in fiscal Q1 2026 compared to fiscal Q1 2025, largely due to a significant decrease in immigration testing demand in the United States and the Middle East. Additionally, Qiagen cited sustained caution among U.S. Life Sciences customers as another headwind impacting performance. The underperformance of a key product segment and broader customer conservatism acted as a drag on the stock, preventing substantial gains during the period.
Show more
Qiagen (QGEN) stock has lost about 5% since 3/31/2026 because of the following key factors:
1. Mixed fiscal Q1 2026 Performance and Revised Full-Year Outlook.
Qiagen (QGEN) reported adjusted diluted EPS of $0.54 for fiscal Q1 2026 (ended March 31, 2026), which was in line with some analyst estimates but missed others by approximately 1.82% to 2.09%. While reported net sales increased 2% to $492 million, they declined 1% at constant exchange rates (CER) against an outlook for at least 1% CER growth, also falling short of consensus estimates. This mixed performance led the company to revise its full-year 2026 outlook, reducing expected net sales growth to about 1-2% CER (from at least 5% CER) and lowering adjusted diluted EPS expectations to at least $2.43 CER (from at least $2.50 CER). This downward adjustment in guidance likely tempered investor enthusiasm, contributing to the stock's stable trend rather than upward momentum.
2. Significant Decline in QuantiFERON Sales and U.S. Life Sciences Customer Caution.
A primary factor behind the revised outlook was a notable 5% CER decline in QuantiFERON sales in fiscal Q1 2026 compared to fiscal Q1 2025, largely due to a significant decrease in immigration testing demand in the United States and the Middle East. Additionally, Qiagen cited sustained caution among U.S. Life Sciences customers as another headwind impacting performance. The underperformance of a key product segment and broader customer conservatism acted as a drag on the stock, preventing substantial gains during the period.
3. Offsetting Growth in Other Business Areas and Positive Future Expectations.
Despite the challenges in QuantiFERON, Qiagen's other growth pillars demonstrated solid performance in fiscal Q1 2026, with Sample technologies growing 9% CER, QIAcuity digital PCR achieving double-digit CER sales growth, and QIAGEN Digital Insights posting single-digit gains. These segments collectively grew 4% CER compared to fiscal Q1 2025. Furthermore, management expressed expectations for stronger growth trends in the second half of 2026, driven by new product launches (anticipated to add about 2 percentage points to growth) and contributions from the Parse acquisition. This blend of current internal growth and optimistic forward guidance helped to stabilize the stock, preventing a sharper decline from the negative news.
4. Neutral Analyst Sentiment and Modest Price Targets.
During the period, analyst sentiment for Qiagen remained largely neutral or "Hold," with a consensus rating of "Hold" from 13 Wall Street analysts as of July 1, 2026. The average 12-month price target ranged from $41.00 to $43.15, implying a relatively modest upside of around 4% to 10.20% from the stock's price around $39.10-$39.41. While some analysts maintained a positive long-term outlook due to the company's competitive position, the lack of strong "Buy" recommendations or significant upside potential in price targets contributed to the stock's tendency to remain at a similar level.
5. Mixed Macroeconomic and Industry Environment.
The broader life sciences market during fiscal Q2 2026 presented a mixed picture, with continued momentum in manufacturing, steady clinical trial activity, and increasing investments in AI-enabled research balancing against several headwinds. Economic uncertainty, intensifying competition (55% of C-suite executives cited this as a top factor holding back growth), supply chain restrictions (47%), and funding challenges in the R&D sector constrained overall growth. Geopolitical uncertainty and the impact of tariffs also contributed to a cautious investment environment. These countervailing macroeconomic forces likely contributed to Qiagen's stock largely staying at the same level, as industry-wide optimism and specific company strengths were offset by general market caution.
Show less
Stock Movement Drivers
Fundamental Drivers
The -3.1% change in QGEN stock from 3/31/2026 to 7/6/2026 was primarily driven by a -5.7% change in the company's Net Income Margin (%).| (LTM values as of) | 3312026 | 7062026 | Change |
|---|---|---|---|
| Stock Price ($) | 40.04 | 38.80 | -3.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,090 | 2,099 | 0.4% |
| Net Income Margin (%) | 20.3% | 19.2% | -5.7% |
| P/E Multiple | 19.4 | 20.0 | 2.8% |
| Shares Outstanding (Mil) | 206 | 207 | -0.4% |
| Cumulative Contribution | -3.1% |
Market Drivers
3/31/2026 to 7/6/2026| Return | Correlation | |
|---|---|---|
| QGEN | -3.1% | |
| Market (SPY) | 15.5% | 23.9% |
| Sector (XLV) | 10.5% | 46.5% |
Fundamental Drivers
The -13.9% change in QGEN stock from 12/31/2025 to 7/6/2026 was primarily driven by a -12.8% change in the company's P/E Multiple.| (LTM values as of) | 12312025 | 7062026 | Change |
|---|---|---|---|
| Stock Price ($) | 45.05 | 38.80 | -13.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,071 | 2,099 | 1.4% |
| Net Income Margin (%) | 19.6% | 19.2% | -2.1% |
| P/E Multiple | 22.9 | 20.0 | -12.8% |
| Shares Outstanding (Mil) | 206 | 207 | -0.5% |
| Cumulative Contribution | -13.9% |
Market Drivers
12/31/2025 to 7/6/2026| Return | Correlation | |
|---|---|---|
| QGEN | -13.9% | |
| Market (SPY) | 10.5% | 9.2% |
| Sector (XLV) | 5.1% | 28.4% |
Fundamental Drivers
The -19.0% change in QGEN stock from 6/30/2025 to 7/6/2026 was primarily driven by a -82.1% change in the company's P/E Multiple.| (LTM values as of) | 6302025 | 7062026 | Change |
|---|---|---|---|
| Stock Price ($) | 47.89 | 38.80 | -19.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,003 | 2,099 | 4.8% |
| Net Income Margin (%) | 4.7% | 19.2% | 309.7% |
| P/E Multiple | 111.6 | 20.0 | -82.1% |
| Shares Outstanding (Mil) | 218 | 207 | 5.5% |
| Cumulative Contribution | -19.0% |
Market Drivers
6/30/2025 to 7/6/2026| Return | Correlation | |
|---|---|---|
| QGEN | -19.0% | |
| Market (SPY) | 22.6% | 11.1% |
| Sector (XLV) | 21.7% | 37.3% |
Fundamental Drivers
The -11.0% change in QGEN stock from 6/30/2023 to 7/6/2026 was primarily driven by a -20.9% change in the company's P/E Multiple.| (LTM values as of) | 6302023 | 7062026 | Change |
|---|---|---|---|
| Stock Price ($) | 43.60 | 38.80 | -11.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,999 | 2,099 | 5.0% |
| Net Income Margin (%) | 17.7% | 19.2% | 8.5% |
| P/E Multiple | 25.2 | 20.0 | -20.9% |
| Shares Outstanding (Mil) | 204 | 207 | -1.3% |
| Cumulative Contribution | -11.0% |
Market Drivers
6/30/2023 to 7/6/2026| Return | Correlation | |
|---|---|---|
| QGEN | -11.0% | |
| Market (SPY) | 75.5% | 31.8% |
| Sector (XLV) | 27.7% | 46.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| QGEN Return | 5% | -10% | -13% | 6% | 2% | -11% | -22% |
| Peers Return | 32% | -27% | -13% | -1% | 1% | 3% | -13% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| QGEN Win Rate | 50% | 58% | 33% | 58% | 67% | 57% | |
| Peers Win Rate | 73% | 37% | 48% | 47% | 50% | 49% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| QGEN Max Drawdown | -17% | -26% | -30% | -13% | -20% | -41% | |
| Peers Max Drawdown | -19% | -39% | -39% | -23% | -39% | -28% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, BIO, ILMN, DHR, A.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/6/2026 (YTD)
How Low Can It Go
| Event | QGEN | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -24.2% | -9.5% |
| % Gain to Breakeven | 32.0% | 10.5% |
| Time to Breakeven | 198 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -10.1% | -6.7% |
| % Gain to Breakeven | 11.2% | 7.1% |
| Time to Breakeven | 636 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -24.7% | -24.5% |
| % Gain to Breakeven | 32.8% | 32.4% |
| Time to Breakeven | 1211 days | 427 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -11.9% | -19.2% |
| % Gain to Breakeven | 13.5% | 23.8% |
| Time to Breakeven | 30 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -12.3% | -3.7% |
| % Gain to Breakeven | 14.0% | 3.9% |
| Time to Breakeven | 5 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -27.5% | -12.2% |
| % Gain to Breakeven | 38.0% | 13.9% |
| Time to Breakeven | 272 days | 62 days |
In The Past
Qiagen's stock fell -3.6% during the 2025 US Tariff Shock. Such a loss loss requires a 3.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | QGEN | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -24.2% | -9.5% |
| % Gain to Breakeven | 32.0% | 10.5% |
| Time to Breakeven | 198 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -24.7% | -24.5% |
| % Gain to Breakeven | 32.8% | 32.4% |
| Time to Breakeven | 1211 days | 427 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -27.5% | -12.2% |
| % Gain to Breakeven | 38.0% | 13.9% |
| Time to Breakeven | 272 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -29.3% | -17.9% |
| % Gain to Breakeven | 41.3% | 21.8% |
| Time to Breakeven | 328 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -41.8% | -53.4% |
| % Gain to Breakeven | 71.8% | 114.4% |
| Time to Breakeven | 324 days | 1085 days |
In The Past
Qiagen's stock fell -3.6% during the 2025 US Tariff Shock. Such a loss loss requires a 3.7% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Qiagen (QGEN)
QIAGEN N.V. (QGEN) specializes in providing "sample to insight" solutions, which means they help transform biological materials into valuable molecular insights worldwide. A fundamental aspect of their business involves supplying essential primary and secondary sample technology consumables, such as kits for nucleic acid stabilization and purification, alongside instruments designed for efficient nucleic acid processing. These foundational products are critical for preparing biological samples for advanced analysis.
The company offers a comprehensive range of diagnostic assays and analytical tools. This includes assays for infectious diseases (like TB, HPV, and STDs), prenatal testing, post-transplant monitoring, and the detection of genomic variants such as mutations. They also provide extensive PCR consumables and instruments, including digital PCR solutions, as well as Next-Generation Sequencing (NGS) products like gene panels and library preparation kits. Complementing these offerings, Qiagen delivers bioinformatics solutions for data analysis and provides custom laboratory and genomic services.
Qiagen serves a diverse global clientele spanning key markets. Their primary customers include organizations in molecular diagnostics, academic research institutions, pharmaceutical companies, and various applied testing sectors, which encompass human identification, forensics, and food contamination analysis. Through their integrated solutions, Qiagen empowers these customers to gain critical molecular understanding and make informed decisions.
AI Analysis | Feedback
They are like the **Intel** for molecular biology labs, providing the essential 'processors' and 'chipsets' (reagents, instruments, and software) that power genetic analysis and discovery.
Qiagen is like the **Snap-on Tools** for molecular biologists, offering specialized, high-quality kits and instruments for genetic analysis.
AI Analysis | Feedback
- Nucleic Acid Sample Processing Kits & Consumables: Kits and technologies for stabilizing, purifying, and processing nucleic acids from primary and secondary biological samples.
- Nucleic Acid Purification Instruments: Manual and automated instruments designed for the purification of nucleic acids and related accessories.
- Diagnostic Assays: Tests for TB, post-transplant monitoring, viral load, prenatal screening, STDs, HPV, human identification, forensics, and food contamination.
- Genomic Variant Analysis Assays: Kits for detecting genomic variants such as mutations, insertions, deletions, and fusions.
- PCR Products: Consumables (e.g., qPCR, reverse transcription kits) and instruments (including digital PCR solutions) for gene expression, genotyping, and regulation analysis.
- Next-Generation Sequencing (NGS) Products: Predefined and custom gene panels, library preparation kits, and whole genome amplification solutions.
- Sample-to-Insight Instruments: Integrated systems for one-step molecular analysis, including hard-to-diagnose syndromes and comprehensive PCR testing.
- Bioinformatics Solutions: Software and tools for analyzing and interpreting molecular data.
- Custom Laboratory and Genomic Services: Specialized laboratory testing and genomic analysis provided on a custom basis.
- OEM Consumables: Custom-developed and configured consumables provided to other equipment manufacturers.
AI Analysis | Feedback
Qiagen (QGEN) primarily serves other companies and institutions rather than individuals. Based on the provided company description, its major customer categories are:
- Molecular diagnostics customers
- Academia
- Pharmaceutical customers
- Applied testing customers
The company description specifies these categories of customers but does not list the names of specific public or private customer companies within these sectors.
AI Analysis | Feedback
AI Analysis | Feedback
Thierry Bernard, Chief Executive Officer and Managing Director
Thierry Bernard joined QIAGEN in February 2015 to lead the company's growing presence in molecular diagnostics, the application of Sample to Insight solutions for molecular testing in human healthcare. He was named Chief Executive Officer in March 2020 after serving in this role on an interim basis since October 2019, and became a member of the Managing Board in 2021. Previously, Mr. Bernard held roles of increasing responsibility for 15 years with bioMérieux SA, most recently as Corporate Vice President, Global Commercial Operations, Investor Relations and the Greater China Region. He also held senior management roles in several other leading international companies. He is a member of the AdvaMedDx Board of Directors, a U.S. industry trade association, and joined the Board of Directors of Neogen Corporation in 2024.
Roland Sackers, Chief Financial Officer and Managing Director
Roland Sackers joined QIAGEN in 1999 as Vice President Finance and has served as Chief Financial Officer since 2004. He became a member of the Managing Board in 2006. Prior to joining QIAGEN, he was an auditor with Arthur Andersen Wirtschaftsprüfungsgesellschaft Steuerberatungsgesellschaft from 1995 to 1999. Mr. Sackers has also held numerous directorships and leadership positions in various companies; he is presently Chairman for Research Biolabs Pte Ltd., CFO, Secretary, Treasurer & Director at Qiagen Beverly, Inc., and Chief Financial Officer & Managing Director at QIAGEN NV, among other roles across 51 different companies. He is also on the board of 55 other companies. Since 2019, he has served on the Supervisory Board of Evotec SE, becoming Chair of the Audit Committee in 2019 and Vice Chair of the Supervisory Board in 2021. He is also Chair of the Board of the German industry association BIO Deutschland.
Fernando Beils, Senior Vice President, Head of Global Commercial Operations
Fernando Beils serves as the Senior Vice President, Head of Global Commercial Operations at QIAGEN.
Stephany Foster, Senior Vice President, Head of Human Resources
Stephany Foster is the Senior Vice President, Head of Human Resources at QIAGEN.
Jean-Pascal Viola, Senior Vice President, Head of Corporate Strategy & Business Development
Jean-Pascal Viola serves as the Senior Vice President, Head of Corporate Strategy & Business Development. He has also been Head of Corporate Business Development & Intellectual Property & Litigation and Senior Vice President at Qiagen N.V.
AI Analysis | Feedback
The key risks to Qiagen's business include:
- Post-pandemic transition and acceleration of growth in the core non-COVID portfolio: Qiagen experienced a significant increase in demand for its testing products during the COVID-19 pandemic, which inflated its revenue and profitability. As this demand normalizes, the company faces challenging year-over-year comparisons and must accelerate growth in its core portfolio, excluding COVID-related products. This is described as the most significant challenge currently facing the company. Investors are now focused on the performance of key growth areas such as the QuantiFERON latent TB test, QIAstat-Dx for syndromic testing, and its digital PCR offerings.
- Intense competition: Qiagen operates in a highly competitive market within the life sciences and diagnostics landscape. The company faces increasing competition from firms offering competing pre-analytical solutions and other products. This competitive landscape is shifting, with major players like Roche preparing to enter the latent tuberculosis testing market, which is a key growth pillar for Qiagen. Competitors may possess significant advantages in financial, operational, sales, marketing, and research and development resources.
- Macroeconomic challenges and international operational risks: As a company with over 50% of its revenues from international markets, Qiagen is highly exposed to the risk of foreign currency fluctuations, which can negatively impact its financial results. Additionally, the company faces geopolitical trade friction, such as U.S.-China tariffs, which are anticipated to create headwinds on adjusted gross margin. Challenges in the China market also continue to temper overall performance. Furthermore, a significant decrease in life sciences research and development expenditures by pharmaceutical and biotechnology companies, academic institutions, or government and private laboratories could seriously damage Qiagen's business.
AI Analysis | Feedback
- CRISPR-based Molecular Diagnostics: Qiagen offers a wide array of diagnostic assays for various applications (e.g., TB testing, viral load monitoring, prenatal testing, sexually transmitted diseases, HPV, genomic variants) and PCR consumables. The emergence of CRISPR-based diagnostic platforms (such as SHERLOCK and DETECTR) represents a fundamental shift in molecular detection. These systems utilize CRISPR-Cas enzymes for highly sensitive, specific, and rapid detection of nucleic acids, often isothermally (without a thermocycler) and with significantly simpler sample preparation. This technology is highly amenable to point-of-care and decentralized testing environments, potentially offering a faster, simpler, and more cost-effective alternative that could directly displace demand for Qiagen’s traditional PCR-based diagnostics, associated consumables, and some sample preparation components.
- Advances in Nanopore Sequencing Technology: Qiagen provides NGS gene panels, library prep kits, and bioinformatics solutions for various applications. While Qiagen offers NGS solutions, the rapid development and increasing adoption of nanopore sequencing technology (e.g., from Oxford Nanopore Technologies) presents a distinct emerging threat. Nanopore sequencing offers unique capabilities such as real-time, long-read sequencing, and portability, often with lower capital expenditure requirements for sequencing instruments compared to traditional short-read sequencers. As accuracy, throughput, and ease of use continue to improve, this technology could disrupt Qiagen’s market for traditional short-read NGS library prep kits and gene panels by offering an alternative sequencing paradigm that may require different or fewer upstream consumables, or provide capabilities (like direct RNA sequencing or rapid pathogen identification) that shift market demand away from existing solutions. Its portability could also challenge the need for centralized laboratory instruments and assays for certain applications.
AI Analysis | Feedback
For Qiagen (symbol: QGEN), the addressable markets for its main products and services are significant and span across various molecular diagnostics and life science research areas:
-
Total Addressable Market: Qiagen estimates its total addressable global market for its portfolio to be more than $11 billion in 2024, with projections to grow to $13-14 billion by 2028.
-
Nucleic Acid Isolation and Purification: The global market for nucleic acid isolation and purification, which includes primary and secondary sample technology consumables and instruments, was valued at approximately USD 6.05 billion in 2025 and is anticipated to reach USD 12.84 billion by 2033, growing at a compound annual growth rate (CAGR) of 10.07% from 2026 to 2033. North America held the largest share of this market, accounting for 41.29% in 2025.
-
Molecular Diagnostics: The global molecular diagnostics market, encompassing various diagnostic assays for genotyping, gene expression, and viral/bacterial analysis, was estimated at USD 18.85 billion in 2025 and is projected to reach USD 25.59 billion by 2033. Other estimates place the global market at USD 45.11 billion in 2025, predicted to increase to USD 66.34 billion by 2035. North America consistently holds the largest share, at around 44.06% in 2025.
-
Tuberculosis (TB) Testing (Interferon-gamma release assays like QuantiFERON): The global tuberculosis diagnostics test market was estimated at approximately USD 2.4 billion in 2024 and is expected to grow to USD 4.1 billion by 2034. Qiagen itself estimates the latent tuberculosis testing market to be around $1.5 billion to $1.6 billion in 2024/2026.
-
Human Papillomavirus (HPV) Testing: The global human papillomavirus (HPV) testing market size is projected to rise from US$ 1.4 billion in 2025 to US$ 2.816 billion by 2032. Another report estimated the global HPV testing and Pap test market size at USD 3.34 billion in 2024, projected to reach USD 6.18 billion by 2033. The global Cytology HPV Testing market alone is estimated to be USD 12.48 billion in 2025.
-
Polymerase Chain Reaction (PCR) Products: The global polymerase chain reaction (PCR) devices market was valued at USD 25.95 billion in 2024 and is expected to reach USD 31.37 billion by 2032. Another report indicated the global PCR technologies market was valued at $14.61 billion in 2024 and is projected to reach $21.89 billion by 2030. North America represents a significant portion of this market, holding a 36.4% share in 2023.
-
Next-Generation Sequencing (NGS) Products: The global next-generation sequencing market was valued at USD 10.44 billion in 2025 and is projected to grow to USD 38.34 billion by 2034. Other estimates range from USD 15.53 billion in 2025 to USD 60.33 billion by 2034 and USD 14.25 billion in 2025 to USD 103.24 billion by 2035. North America held a substantial market share, at approximately 56.01% in 2025.
AI Analysis | Feedback
Qiagen (QGEN) is expected to drive future revenue growth over the next 2-3 years through a combination of sustained performance from its established "growth pillars," the introduction of new products and advanced automation solutions, and strategic acquisitions that expand its technological capabilities and market reach.
Here are the key drivers:
- Sustained Growth of Core "Growth Pillars": Qiagen anticipates continued strong performance and expansion across its five key growth pillars: Sample technologies, QuantiFERON (for latent tuberculosis testing), QIAstat (syndromic testing), QIAcuity (digital PCR), and QIAGEN Digital Insights (bioinformatics). These pillars collectively are targeted to achieve at least $2 billion in combined annual sales by 2028 and are expected to deliver around 9% constant exchange rate (CER) growth in 2026. The QuantiFERON franchise, for instance, continues to benefit from the conversion in the latent TB testing market.
- New Product Launches and Enhanced Automation: The company is focused on introducing new products and enhancing its automation offerings to expand addressable markets and increase recurring consumables and software revenues. Planned launches include new sample preparation systems such as QIAsprint Connect, QIAmini, and QIAsymphony Connect, designed to meet demand for varying throughput levels. Additionally, Qiagen is expanding assay panels for platforms like QIAstat-Dx, with new panels for bloodstream infections, sepsis-related applications, and FDA clearance for GI panels on the QIAstat-Dx Rise platform. Innovations in QuantiFERON are also expected, including enhanced automation and AI-based results, along with the European launch of the next-gen QuantiFERON TB Gold Plus assay and a planned U.S. launch in 2026.
- Strategic Acquisitions and Portfolio Expansion: Recent strategic acquisitions are poised to contribute significantly to revenue growth. The acquisition of Parse Biosciences in December 2025 notably expanded Qiagen's Sample technologies portfolio into the rapidly growing single-cell analysis market. Parse Biosciences is projected to contribute at least $40 million in sales in 2026, with opportunities to scale through Qiagen's global commercial infrastructure. Furthermore, the integration of Genoox has strengthened the company's AI-driven clinical interpretation offerings within QIAGEN Digital Insights, enhancing its bioinformatics portfolio. Qiagen is also developing 14 AI-enabled software solutions over the next two years.
AI Analysis | Feedback
Share Repurchases
- QIAGEN completed a $500 million synthetic share repurchase on January 7, 2026, which involved a direct payment to shareholders combined with a reverse stock split (20 issued shares consolidated into 19), reducing outstanding shares by approximately 5%.
- Since early 2024, QIAGEN has returned approximately $1.15 billion to shareholders, including a previous synthetic share repurchase and its first annual dividend payment in June 2025. This fulfills its commitment to return at least $1 billion to shareholders by the end of 2028 ahead of schedule.
- In early 2024 and late January 2025, QIAGEN conducted synthetic share repurchases of approximately $300 million each, contributing to a total of about $600 million towards the $1 billion shareholder return commitment.
Outbound Investments
- QIAGEN completed the acquisition of Parse Biosciences in December 2025 to expand its Sample technologies portfolio into single-cell analysis. This acquisition is expected to contribute approximately $40 million in sales in 2026.
- In May 2025, QIAGEN acquired Genoox for $70 million to strengthen its clinical genomics portfolio.
- QIAGEN acquired Blirt in May 2022 for an undisclosed amount.
Capital Expenditures
- Capital expenditures for property, plant, and equipment were $167.174 million in 2024, $149.710 million in 2023, $129.224 million in 2022, and $189.904 million in 2021.
- In the last 12 months (prior to February 2026), capital expenditures totaled approximately -$201.05 million.
- The primary focus of capital expenditures includes significant investments in research and development to expand the molecular diagnostic market presence, with plans to launch three new sample preparation systems in 2026 focusing on automation and throughput for applications such as liquid biopsy, minimal residual disease testing, and microbiome research. QIAGEN is also investing in automation, menu expansion, and artificial intelligence (AI).
Latest Trefis Analyses
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 193.98 |
| Mkt Cap | 33.3 |
| Rev LTM | 5,812 |
| Op Inc LTM | 1,208 |
| FCF LTM | 1,030 |
| FCF 3Y Avg | 1,005 |
| CFO LTM | 1,290 |
| CFO 3Y Avg | 1,268 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 4.4% |
| Rev Chg 3Y Avg | 0.5% |
| Rev Chg Q | 4.2% |
| QoQ Delta Rev Chg LTM | 1.0% |
| Op Inc Chg LTM | 2.5% |
| Op Inc Chg 3Y Avg | 1.2% |
| Op Mgn LTM | 19.4% |
| Op Mgn 3Y Avg | 18.7% |
| QoQ Delta Op Mgn LTM | 0.3% |
| CFO/Rev LTM | 22.9% |
| CFO/Rev 3Y Avg | 22.3% |
| FCF/Rev LTM | 17.1% |
| FCF/Rev 3Y Avg | 17.8% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Diagnostic solutions | 803 | 749 | 698 | 661 | 639 |
| Sample technologies | 661 | 642 | 663 | 797 | 851 |
| Polymerase Chain Reaction (PCR) / Nucleic acid amplification | 309 | 300 | 300 | 391 | 434 |
| Genomics / Next-Generation Sequencing (NGS) | 242 | 234 | 239 | 225 | 245 |
| Other | 75 | 53 | 66 | 68 | 83 |
| Total | 2,090 | 1,978 | 1,965 | 2,142 | 2,252 |
Price Behavior
| Market Price | $38.80 | |
| Market Cap ($ Bil) | 8.0 | |
| First Trading Date | 06/28/1996 | |
| Distance from 52W High | -30.3% | |
| 50 Days | 200 Days | |
| DMA Price | $36.13 | $43.62 |
| DMA Trend | down | down |
| Distance from DMA | 7.4% | -11.0% |
| 3M | 1YR | |
| Volatility | 37.3% | 32.1% |
| Downside Capture | 51.79 | 54.47 |
| Upside Capture | 9.07 | 15.74 |
| Correlation (SPY) | 25.8% | 11.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.28 | 0.31 | 0.72 | 0.30 | 0.31 | 0.56 |
| Up Beta | 0.60 | 0.94 | 1.07 | 0.91 | 0.68 | 0.77 |
| Down Beta | 2.01 | 1.68 | 0.92 | -0.22 | -0.20 | 0.29 |
| Up Capture | 0% | 9% | 27% | 6% | 15% | 19% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 11 | 22 | 30 | 53 | 118 | 361 |
| Down Capture | -75% | -97% | 72% | 55% | 66% | 86% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 10 | 19 | 33 | 71 | 133 | 383 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QGEN | |
|---|---|---|---|---|
| QGEN | -20.4% | 32.0% | -0.69 | - |
| Sector ETF (XLV) | 21.3% | 15.6% | 1.04 | 37.8% |
| Equity (SPY) | 22.2% | 12.5% | 1.32 | 11.0% |
| Gold (GLD) | 23.7% | 27.8% | 0.75 | 21.8% |
| Commodities (DBC) | 21.2% | 18.6% | 0.90 | -10.1% |
| Real Estate (VNQ) | 12.4% | 13.8% | 0.61 | 23.6% |
| Bitcoin (BTCUSD) | -43.6% | 42.7% | -1.23 | 0.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QGEN | |
|---|---|---|---|---|
| QGEN | -3.8% | 25.6% | -0.16 | - |
| Sector ETF (XLV) | 6.8% | 14.9% | 0.27 | 50.1% |
| Equity (SPY) | 13.5% | 17.1% | 0.61 | 40.7% |
| Gold (GLD) | 18.1% | 18.3% | 0.80 | 14.6% |
| Commodities (DBC) | 7.3% | 19.5% | 0.27 | -2.9% |
| Real Estate (VNQ) | 2.7% | 18.9% | 0.05 | 40.0% |
| Bitcoin (BTCUSD) | 14.2% | 53.6% | 0.45 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with QGEN | |
|---|---|---|---|---|
| QGEN | 6.0% | 27.1% | 0.25 | - |
| Sector ETF (XLV) | 10.4% | 16.6% | 0.51 | 39.9% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 34.2% |
| Gold (GLD) | 12.3% | 16.1% | 0.62 | 11.7% |
| Commodities (DBC) | 5.8% | 18.0% | 0.25 | 5.0% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 25.7% |
| Bitcoin (BTCUSD) | 58.3% | 66.2% | 0.98 | 7.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| SUMMARY STATS | |||
| # Positive | 0 | 0 | 0 |
| # Negative | 0 | 0 | 0 |
| Median Positive | |||
| Median Negative | |||
| Max Positive | |||
| Max Negative | |||
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 6-K |
| 12/31/2025 | 03/20/2026 | 20-F |
| 09/30/2025 | 11/06/2025 | 6-K |
| 06/30/2025 | 08/21/2025 | 6-K |
| 03/31/2025 | 05/13/2025 | 6-K |
| 12/31/2024 | 03/31/2025 | 20-F |
| 09/30/2024 | 11/08/2024 | 6-K |
| 06/30/2024 | 08/02/2024 | 6-K |
| 03/31/2024 | 05/01/2024 | 6-K |
| 12/31/2023 | 03/11/2024 | 20-F |
| 09/30/2023 | 11/01/2023 | 6-K |
| 06/30/2023 | 08/10/2023 | 6-K |
| 03/31/2023 | 05/05/2023 | 6-K |
| 12/31/2022 | 03/13/2023 | 20-F |
| 09/30/2022 | 11/09/2022 | 6-K |
| 06/30/2022 | 07/29/2022 | 6-K |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/08/2026 | 6-K |
| 12/31/2025 | 03/20/2026 | 20-F |
| 09/30/2025 | 11/06/2025 | 6-K |
| 06/30/2025 | 08/21/2025 | 6-K |
| 03/31/2025 | 05/13/2025 | 6-K |
| 12/31/2024 | 03/31/2025 | 20-F |
| 09/30/2024 | 11/08/2024 | 6-K |
| 06/30/2024 | 08/02/2024 | 6-K |
| 03/31/2024 | 05/01/2024 | 6-K |
| 12/31/2023 | 03/11/2024 | 20-F |
| 09/30/2023 | 11/01/2023 | 6-K |
| 06/30/2023 | 08/10/2023 | 6-K |
| 03/31/2023 | 05/05/2023 | 6-K |
| 12/31/2022 | 03/13/2023 | 20-F |
| 09/30/2022 | 11/09/2022 | 6-K |
| 06/30/2022 | 07/29/2022 | 6-K |
| 03/31/2022 | 04/29/2022 | 6-K |
| 12/31/2021 | 03/14/2022 | 20-F |
| 09/30/2021 | 11/08/2021 | 6-K |
| 06/30/2021 | 08/02/2021 | 6-K |
| 03/31/2021 | 05/05/2021 | 6-K |
| 12/31/2020 | 03/05/2021 | 20-F |
| 09/30/2020 | 11/02/2020 | 6-K |
| 06/30/2020 | 08/05/2020 | 6-K |
| 03/31/2020 | 05/08/2020 | 6-K |
| 12/31/2019 | 03/02/2020 | 20-F |
| 09/30/2019 | 10/31/2019 | 6-K |
| 06/30/2019 | 08/01/2019 | 6-K |
Qiagen — Investor Video Playlist
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Life Sciences Tools & Services Resources |
| GenomeWeb |
| BioSpace |
| The Scientist |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.